Loading…
← CockpitCompetitor Analysis › 301108.SZ Tongling Jieya Biologic Technology Co., Ltd. Class AOpen in the cockpit ↗

Tongling Jieya Biologic Technology Co., Ltd. Class A301108.SZCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Household/Personal Care

Tongling-based biologic/personal-care technology company; specific product lines not independently confirmed.

Momentum leader 98
Mkt cap
$933M
US dollars, full cap
$/day
$9.72M
20-day average traded
Fwd P/E
52.5×
forward earnings
ROIC−WACC
-0.7 pp
WACC 6.2%
Hurdle
+28 pp
Req g minus delivered
Next earnings
148 days
15 Apr 2027
Close · CNYCN¥39.50
1D+0.8%
1W-9.0%
1M-21.1%
3M+7.3%
6M+56.2%
YTD+18.8%
1Y+19.5%
ATR %6.9%
52w lowhigh30.2% off high

What Tongling Jieya Biologic Technology does

Tongling-based biologic/personal-care technology company; specific product lines not independently confirmed.

Where it sits in the supply chain

  • Consumer staples
  • Household/personal care

Moat: none

Headquarters: Tongling, China · Employees: 647

Tongling Jieya Biologic Technology at a glance

Size Tongling Jieya Biologic Technology (301108.SZ) is a China Consumer Staples company (Household/Personal Care) with a market value of $933M, the 2291st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥39.50 on 18 Nov 2026.

Performance Over six months the shares gained 56.2%, against +4.3% for the median peer and -20.0% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 24.3% over the last twelve months (peer median +10.2%); the operating margin is 5.0% (peer median 8.9%).

Valuation It trades at 52.5× forward earnings against a peer median of 18.7× (most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.7 points below its cost of capital (6.2% WACC).

Next results Next results expected around 15 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026301108.SZ 156Peer median 107
Six months, rebased to 100: Tongling Jieya Biologic Technology against the median of its 20 peers (local-currency closes).

Tongling Jieya Biologic Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥875MCN¥771MCN¥546MCN¥618MCN¥664M
Revenue growth—+41%-12%-7%—
Gross profitCN¥234MCN¥178MCN¥94.9MCN¥173MCN¥203M
EBITDAn/aCN¥130MCN¥62.7MCN¥136MCN¥169M
Net incomeCN¥54.5MCN¥77.3MCN¥19.5MCN¥115MCN¥141M
Free cash flowCN¥30.1M-CN¥219MCN¥20.7MCN¥11.3MCN¥282M
Capital expenditureCN¥219MCN¥368MCN¥96.2MCN¥85.1MCN¥29.9M
Total debtCN¥336MCN¥172MCN¥80.1MCN¥105MCN¥121M

Quarterly statements and history in the cockpit →

Tongling Jieya Biologic Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%6031930013284928241710GALAXYSURF2657300740483650JYOTHYLAB21454919605009EPC003006ICOS301371BAJAJCON002790603983301108.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Tongling Jieya Biologic Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×6031930013284928241710GALAXYSURF2657300740483650JYOTHYLAB21454919605009EPC003006ICOS301371BAJAJCON002790600315603983301108.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tongling Jieya Biologic Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%6031930013284928GALAXYSURF2657300740483650JYOTHYLAB21454919003006301371002790600315301108.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tongling Jieya Biologic Technology is the large dot.

Tongling Jieya Biologic Technology competitors and peer comparison

How Tongling Jieya Biologic Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tongling Jieya Biologic Technology against its 20 peers (data as of 18 Nov 2026)
Measure301108.SZPeer medianRank in peer set
1-month return-21.1%-1.6%3rd lowest of 21
6-month return+56.2%+4.3%2nd highest of 21
Distance from 52-week high-30.2%-33.1%10th highest of 21
Revenue growth (TTM)+24.3%+10.2%7th highest of 21
Operating margin5.0%8.9%5th lowest of 21
Forward P/E52.5×18.7×most expensive of 21
Growth the price implies (Req g, 7 yrs)28.5%4.4%3rd most demanding of 18
Growth delivered (Del g)+0.8%+8.9%3rd lowest of 18
Hurdle (Req g minus delivered)+27.7 pp-4.4 ppmost demanding of 18
ROIC minus cost of capital-0.7 pp+7.1 pp6th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tongling Jieya Biologic Technology 301108.SZChina$933M+56%+24%5%52.5×28.5%+0.8%
Runben Biotechnology 603193.SSChina$918M-30%+13%21%18.5×1.5%+28.4%
Dencare (Chongqing) Oral Care 001328.SZChina$912M+13%+10%11%27.9×3.7%+10.8%
Noevir 4928.TJapan$978M+7%-3%28%20.4×-12.8%+4.1%
Cosmecca Korea 241710.KSSouth Korea$847M+23%+42%12%16.3×n/an/a
Galaxy Surfactants GALAXYSURF.NSIndia$845M+22%+30%9%17.6×18.5%+13.7%
Shanghai Forest Cabin Cosmetics 2657.HKHong Kong$1.04B+15%+74%18%11.8×11.3%+49.0%
SYoung 300740.SZChina$816M-48%+14%3%33.4×14.0%+6.1%
d'Alba Global 483650.KSSouth Korea$1.13B-55%+49%22%12.0×-6.6%+53.0%
Jyothy Labs JYOTHYLAB.NSIndia$762M-9%+5%8%40.8×34.5%+8.9%
Shanghai Chicmax Cosmetics 2145.HKHong Kong$1.17B-42%+23%8%14.4×-6.1%+21.2%
Milbon 4919.TJapan$743M+48%+8%14%25.7×-3.3%+8.2%
Hangzhou Haoyue Personal Care 605009.SSChina$726M-18%+10%6%17.7×4.4%+7.7%
Edgewell Personal Care EPCUnited States$1.30B+67%-10%7%14.2×n/an/a
Chongqing Baiya Sanitary Products 003006.SZChina$1.35B+27%0%3%37.3×28.8%+22.8%
Intercos ICOS.MIItaly$1.43B+12%-5%9%18.9×4.3%+11.5%
Harbin Fuerjia Technology 301371.SZChina$1.51B-39%+28%20%21.4×7.5%+3.6%
Bajaj Consumer Care BAJAJCON.NSIndia$560M-24%+29%22%19.7×14.8%+5.0%
AMOREPACIFIC 002790.KSSouth Korea$1.61B+2%+9%9%8.5×-5.7%-1.3%
Shanghai Jahwa United 600315.SSChina$1.61B-15%+9%2%15.4×15.3%-2.1%
Guangdong Marubi Biotechnology 603983.SSChina$1.62B+9%-6%2%45.5×n/an/a

Questions

Which companies are Tongling Jieya Biologic Technology's closest peers?
The cockpit's peer set: Runben Biotechnology (603193.SS), Dencare (Chongqing) Oral Care (001328.SZ), Noevir (4928.T), Cosmecca Korea (241710.KS), Galaxy Surfactants (GALAXYSURF.NS), Shanghai Forest Cabin Cosmetics (2657.HK), SYoung (300740.SZ), d'Alba Global (483650.KS).
Is Tongling Jieya Biologic Technology expensive compared with its peers?
On forward p/e it trades at 52.5× against a peer median of 18.7×, most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Tongling Jieya Biologic Technology stock performed?
Over six months to 18 Nov 2026 the shares returned +56.2% against +4.3% for the median peer; over one year +19.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.